These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2124638

  • 1. [The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects].
    Kobayashi Y, Fukuo Y, Shibuya T, Terashi A.
    Nihon Ronen Igakkai Zasshi; 1990 Sep; 27(5):578-83. PubMed ID: 2124638
    [Abstract] [Full Text] [Related]

  • 2. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A.
    Thromb Haemost; 1990 Feb 19; 63(1):82-6. PubMed ID: 2111051
    [Abstract] [Full Text] [Related]

  • 3. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
    Akanji AO, Abdullah A, Tahzeeb S.
    Eur J Clin Invest; 1997 May 19; 27(5):380-6. PubMed ID: 9179544
    [Abstract] [Full Text] [Related]

  • 4. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia.
    Glueck CJ, Glueck HI, Tracy T, Speirs J, Stroop D.
    Metabolism; 1993 Nov 19; 42(11):1410-9. PubMed ID: 8231835
    [Abstract] [Full Text] [Related]

  • 5. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
    Ruiz-Argüelles GJ, Ruiz-Argüelles A, Lobato-Mendizábal E, Díaz-Gomez F, Pacheco-Pantoja E, Drenkard C, Alarcón-Segovia D.
    Am J Hematol; 1991 May 19; 37(1):9-13. PubMed ID: 1902623
    [Abstract] [Full Text] [Related]

  • 6. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
    Xiong X, Zhao S, Wang Z, Lo L, Huang Q.
    Hunan Yi Ke Da Xue Xue Bao; 1998 May 19; 23(6):555-7. PubMed ID: 10806767
    [Abstract] [Full Text] [Related]

  • 7. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB.
    Stroke; 1996 Jun 19; 27(6):1066-71. PubMed ID: 8650716
    [Abstract] [Full Text] [Related]

  • 8. Activity of tissue plasminogen activator and plasminogen activator inhibitor in noninsulin-dependent diabetes mellitus.
    Matsuo T, Kadowaki S, Okada K, Matsuo O.
    J Diabet Complications; 1990 Jun 19; 4(3):119-21. PubMed ID: 2147433
    [Abstract] [Full Text] [Related]

  • 9. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease.
    Smith FB, Lee AJ, Rumley A, Fowkes FG, Lowe GD.
    Atherosclerosis; 1995 May 19; 115(1):35-43. PubMed ID: 7669086
    [Abstract] [Full Text] [Related]

  • 10. Tissue-type plasminogen activator, plasminogen activator inhibitor, and histidine-rich glycoproteins in stressed human newborns.
    Corrigan JJ, Jeter MA.
    Pediatrics; 1992 Jan 19; 89(1):43-6. PubMed ID: 1728019
    [Abstract] [Full Text] [Related]

  • 11. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
    Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G.
    Circulation; 1998 Nov 24; 98(21):2241-7. PubMed ID: 9826309
    [Abstract] [Full Text] [Related]

  • 12. Fluctuation of TPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and female.
    Urano T, Sumiyoshi K, Nakamura M, Mori T, Takada Y, Takada A.
    Thromb Res; 1990 Oct 01; 60(1):55-62. PubMed ID: 2126149
    [Abstract] [Full Text] [Related]

  • 13. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmed KA, Muniandy S.
    Cardiovasc Diabetol; 2011 Mar 18; 10():23. PubMed ID: 21414238
    [Abstract] [Full Text] [Related]

  • 14. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer.
    Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D.
    Metabolism; 1993 Feb 18; 42(2):236-46. PubMed ID: 8474322
    [Abstract] [Full Text] [Related]

  • 15. Association between tissue plasminogen activator and serum lipids in healthy volunteers.
    Yamada R, Yamada S, Ishii A, Sasamata M, Watanabe S.
    Ann Med; 1990 Feb 18; 22(5):313-8. PubMed ID: 2127223
    [Abstract] [Full Text] [Related]

  • 16. Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men.
    Velthuis-te Wierik EJ, Meijer P, Kluft C, van den Berg H.
    Metabolism; 1995 Dec 18; 44(12):1548-52. PubMed ID: 8786722
    [Abstract] [Full Text] [Related]

  • 17. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.
    Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlén GH.
    Atherosclerosis; 1989 Nov 18; 80(1):9-16. PubMed ID: 2532510
    [Abstract] [Full Text] [Related]

  • 18. Reduced levels of tissue plasminogen activator and plasminogen activator inhibitor in plasma of patients with familial amyloidotic polyneuropathy.
    Olofsson BO, Nilsson TK.
    Haemostasis; 1990 Nov 18; 20(1):31-6. PubMed ID: 2108913
    [Abstract] [Full Text] [Related]

  • 19. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor.
    Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA.
    Arteriosclerosis; 1989 Nov 18; 9(6):934-9. PubMed ID: 2511826
    [Abstract] [Full Text] [Related]

  • 20. [Plasminogen activator inhibitor and protein C: their relation to plasma lipids and lipo- and apoproteins in ischemic heart disease of different duration].
    Zateĭshchikov DA, Gratsianskiĭ NA, Dobrovol'skiĭ AB, Metel'skaia VA, Storozhilova AN, Panchenko EP, Nechaev AS.
    Kardiologiia; 1990 Apr 18; 30(4):47-50. PubMed ID: 2395263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.